Conexeu Sciences (NASDAQ: CNXU) has initiated a preclinical development program for B.R.E.A.S.T. (BIO-REGENERATIVE ERGONOMICALLY ARCHITECTED SMART TISSUE), its recently unveiled 3D-printed bioregenerative breast matrix, at the Wake Forest Institute for Regenerative Medicine (WFIRM).
According to Conexeu, the program will leverage WFIRM’s advanced tissue-organ bioprinting infrastructure to support a comprehensive preclinical study evaluating the durability, host tissue integration, and resorbability of Conexeu’s proprietary CXU 3D-printed B.R.E.A.S.T. matrix. The findings will directly inform the design of future studies and guide progression toward clinical development.
In a statement, Miles Harrison, president and CEO of Conexeu, commented, “This preclinical program design is an important step in the advancement of B.R.E.A.S.T. and our overall regenerative medicine strategy. We believe bioregenerative approaches that work naturally with the body represent a significant evolution beyond traditional implant technologies.”
